Sanofi has grabbed Ablynx from right under Novo Nordisk’s nose. It announced the acquisition of the the Belgian clinical-stage biotech company, Ablynx at €45 per share in cash, reflecting equity value of ~€3.9bn. Novo Nordisk had been pursuing Ablynx and was rebuffed twice for €28 per share in cash and €2.5 per share worth of contingent value rights, valuing the firm at €2.6bn. It was reported to be looking at sweetening the offer further, but has pulled out aft
29 Jan 2018
Buys Ablynx to Nordisk Nordisk’s consternation
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Buys Ablynx to Nordisk Nordisk’s consternation
Sanofi has grabbed Ablynx from right under Novo Nordisk’s nose. It announced the acquisition of the the Belgian clinical-stage biotech company, Ablynx at €45 per share in cash, reflecting equity value of ~€3.9bn. Novo Nordisk had been pursuing Ablynx and was rebuffed twice for €28 per share in cash and €2.5 per share worth of contingent value rights, valuing the firm at €2.6bn. It was reported to be looking at sweetening the offer further, but has pulled out aft